Simulations Plus (SLP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Jul, 2026Executive summary
A special meeting will be held for shareholders to vote on a proposed merger, where shareholders will receive $18.50 per share in cash, a 26% premium to the 60-day average price prior to the merger announcement.
The merger will result in the company becoming a wholly owned subsidiary of SP Evolution HoldCo II, LLC, an affiliate of Altaris, and the company will be delisted from Nasdaq.
The board unanimously recommends voting in favor of the merger, citing a competitive auction process, strategic challenges, and the fairness opinion from Morgan Stanley.
The merger is expected to close in the second half of 2026, subject to regulatory approvals and shareholder approval.
Voting matters and shareholder proposals
Shareholders will vote on: (1) adoption of the merger agreement, (2) advisory approval of executive compensation related to the merger, and (3) adjournment of the meeting if more votes are needed.
Approval of the merger requires a majority of outstanding shares; failure to vote or abstentions count as votes against.
Dissenters' rights are available under California law for shareholders who do not vote in favor and follow strict procedures.
Board of directors and corporate governance
The board conducted a formal auction process, reviewed multiple bids, and selected Altaris as the best offer after negotiations.
The board considered strategic alternatives, industry challenges, and the company's ability to fund AI development.
A voting agreement was entered into with major shareholders, who have agreed to support the merger.
Latest events from Simulations Plus
- Shareholders to vote on $18.50/share cash merger after robust auction and board approval.SLP
Proxy filing - Shareholders to vote on $18.50/share cash merger, with board unanimous support and 26% premium.SLP
Proxy filing - Q3 FY26 revenue up 7%, services up 20%, net income $3.6M, merger at $18.50/share pending.SLP
Q3 2026 - OBESITYsym predicts weight loss and nausea for obesity drugs, validated across diverse populations.SLP
Status update - Q2 2026 revenue up 8% to $24.3M, with higher margins and strong outlook despite EPS guidance cut.SLP
Q2 2026 - Q1 revenue fell 3% to $18.4M as services rose 16%, software dropped 17%, and guidance was reaffirmed.SLP
Q1 2026 - FY25 guidance targets $90M-$93M revenue, 31%-33% EBITDA margin, and expanded market reach.SLP
Stephens 26th Annual Investment Conference | NASH2024 - FY24 revenue up 18% to $70M; FY25 guidance strong with Pro-ficiency driving growth.SLP
Q4 2024 - $100M acquisition doubles market, expands platform, and boosts 2025 EPS outlook.SLP
M&A Announcement